PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Clinical trials for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE trials appear
Sign up with your email to follow new studies for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for Alzheimer's psychosis: new drug aims to stop relapses
Disease control Recruiting nowThis study tests an investigational drug called KarXT to see if it can prevent the return of psychosis (like hallucinations or delusions) in people with Alzheimer's disease. About 410 participants aged 55-90 will receive either KarXT or a placebo for 38 weeks. The main goal is to…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could this pill ease Alzheimer's hallucinations?
Symptom relief Recruiting nowThis Phase 3 trial tests whether the drug KarXT can safely reduce psychosis (hallucinations and delusions) in people with Alzheimer's disease. About 500 participants aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will receive either KarXT or a plac…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug KarXT aims to safely treat Alzheimer's psychosis in Long-Term trial
Symptom relief Recruiting nowThis study is testing the long-term safety of an experimental drug called KarXT for people with Alzheimer's disease who also experience psychosis (hallucinations or delusions). About 800 participants who completed earlier studies will take KarXT for up to 52 weeks. The main goal …
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to quiet Alzheimer's psychosis
Symptom relief Recruiting nowThis Phase 2 study tests an experimental drug, ML-007C-MA, to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 300 participants aged 55 to 90 will receive either the drug or a placebo. The main goal is to measure changes in psycho…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New hope for Alzheimer's psychosis: Long-Term drug trial underway
Symptom relief Recruiting nowThis study is testing the long-term safety of a drug called ML007C-MA for people with Alzheimer's disease who also have hallucinations and delusions. About 210 adults who completed a previous study will take the drug twice daily for up to 52 weeks. The goal is to see if the drug …
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New pill aims to calm Alzheimer's psychosis in landmark trial
Symptom relief Recruiting nowThis study tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis symptoms like hallucinations and delusions in people with Alzheimer's disease. About 370 participants will receive either the drug or a placebo, and doctors will track changes in symptom sev…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC